<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Retinal vasculitis associated with systemic disorders and infections</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Retinal vasculitis associated with systemic disorders and infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Retinal vasculitis associated with systemic disorders and infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reza Dana, MD, MPH, MSc</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A Merkel, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer E Thorne, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Retinal vasculitis is characterized by inflammation of the vessels of the retina [<a href="#rid1">1</a>]. Retinal vasculitis can occur in association with an underlying infectious or systemic disease, as part of an ocular disease, or it can be idiopathic. The detection and characterization of retinal vasculitis may help in the diagnosis and management of certain disorders associated with ocular inflammation.</p><p>This topic will review the clinical features of retinal vasculitis associated with systemic disorders and infections. Vasculitis of the retinal vessels due to local ocular inflammatory disorders is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8231.html" rel="external">"Retinal vasculitis associated with primary ocular disorders"</a>.)</p><p class="headingAnchor" id="H1573543871"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Retinal vasculitis is an inflammatory response isolated to the venous, arterial, or capillary retinal vasculature with inflammation extending towards nonvascular retinal structures with a pattern of extension that demonstrates a retinal blood vessel being the source of the inflammation. This pattern of vasculature-sourced inflammation can be associated with systemic immunologic disorders, systemic infections, or no known systemic association  (<a class="graphic graphic_table graphicRef56959" href="/z/d/graphic/56959.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H3964674596"><span class="h2">Infectious causes</span><span class="headingEndMark"> — </span>A variety of different infections are associated with retinal vasculitis. The most common cause of infectious retinal vasculitis is toxoplasmosis, followed by tuberculosis (TB), syphilis, and herpes viral infections. These and several other types of infections that can cause retinal vasculitis are presented below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxoplasmosis</strong> – Toxoplasmosis accounts for as much as 25 percent of cases of posterior uveitis in the United States [<a href="#rid2">2</a>]. The retina is the primary site of eye infection. Whereas in immunocompromised patients, toxoplasmic involvement of the brain is more common than retinal toxoplasmosis, the reverse is true in immunocompetent individuals. Active lesions usually appear as white focal lesions with a severe vitreous inflammatory reaction  (<a class="graphic graphic_picture graphicRef74181" href="/z/d/graphic/74181.html" rel="external">picture 1</a>). Vitreo-retinitis is a sine qua non of active ocular toxoplasmosis  (<a class="graphic graphic_picture graphicRef62410" href="/z/d/graphic/62410.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent1">The retinal vasculitis usually occurs near active lesions and can affect both venules and arterioles. The arteriolar involvement is often characterized by "skip lesions," in which focal areas of vasculitis are flanked by apparently normal vessels  (<a class="graphic graphic_diagnosticimage graphicRef64718" href="/z/d/graphic/64718.html" rel="external">image 1</a>). Toxoplasmosis is a clinical diagnosis, but serologic studies are helpful in the diagnosis. The diagnosis and treatment of ocular toxoplasmosis are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5699.html" rel="external">"Toxoplasmosis: Ocular disease", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/5699.html" rel="external">"Toxoplasmosis: Ocular disease", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberculosis</strong> – Although TB can affect any tissue in the eye and was once a frequent cause of retinal vasculitis, involvement of the eye is now an uncommon manifestation of extrapulmonary TB, being seen in approximately 1 percent of patients [<a href="#rid3">3,4</a>]. Infection with this organism also represented less than 1 percent of all cases of uveitis in a United States cohort.</p><p></p><p class="bulletIndent1">Retinal involvement is commonly an extension of choroidal disease, which usually results from miliary TB [<a href="#rid5">5,6</a>]. Retinal vasculitis is the most common manifestation of retinal TB [<a href="#rid7">7</a>]. In one series of 12 patients with intraocular TB, 9 had florid ischemic retinal vasculitis [<a href="#rid7">7</a>]. Retinal vasculitis may result in retinal vein occlusion and in subsequent neovascularization [<a href="#rid8">8,9</a>]. (See  <a class="medical medical_review" href="/z/d/html/7999.html" rel="external">"Tuberculosis and the eye"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Whipple's disease</strong> – Whipple's disease is a multisystem infectious disorder characterized by weight loss, diarrhea, abdominal pain, and arthralgias. Ocular involvement of Whipple's disease is uncommon, but includes retinal vasculitis, uveitis, keratitis, vitritis, optic neuritis, and papilledema [<a href="#rid10">10,11</a>]. (See  <a class="medical medical_review" href="/z/d/html/2702.html" rel="external">"Whipple's disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syphilis</strong> – Syphilis can involve almost any structure in the eye [<a href="#rid12">12</a>]. Most patients with ocular syphilis develop diminished visual acuity secondary to posterior uveitis. Retinal vasculitis and other ocular manifestations such as blepharitis, conjunctivitis, iritis, episcleritis, scleritis, chorioretinitis, vitritis, neuroretinitis, disc edema, and retinal detachment can also occur. (See  <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">"Neurosyphilis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lyme disease</strong> – A variety of ocular manifestations have been associated with Lyme disease during early disseminated disease. Retinal vasculitis is rare and has only been described in case reports [<a href="#rid13">13,14</a>]. Because of the variability in Lyme disease presentation, this association of retinal vasculitis is unlikely to be detected since many Lyme disease patients would rarely see an ophthalmologist. (See  <a class="medical medical_review" href="/z/d/html/7913.html" rel="external">"Clinical manifestations of Lyme disease in adults", section on 'Ocular manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cat scratch disease</strong> – Retinal vasculitis is a rare manifestation of cat scratch disease (CSD) [<a href="#rid15">15,16</a>]. Other ocular manifestations of this infection include Parinaud oculoglandular syndrome, neuroretinitis, papillitis, optic neuritis, focal retinochorioretinitis, and retinal vascular occlusions. (See  <a class="medical medical_review" href="/z/d/html/5532.html" rel="external">"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral infections</strong> – Both herpes simplex and varicella-zoster can cause retinal vasculitis. Herpes simplex retinitis occurs in patients who are congenitally infected or immunosuppressed because of chemotherapy. White retinal infiltrates accompanied by a retinal vasculitis are a hallmark finding in this setting.</p><p></p><p class="bulletIndent1">Herpes simplex and varicella-zoster virus are also associated with acute retinal necrosis (ARN), a necrotizing retinitis that may occur in healthy immunocompetent individuals [<a href="#rid17">17,18</a>]. The retinal findings associated with ARN start as patchy white-yellow areas that become confluent over time  (<a class="graphic graphic_picture graphicRef81368" href="/z/d/graphic/81368.html" rel="external">picture 3</a>). Retinal vasculitis with this disorder typically affects the arterioles more than the veins [<a href="#rid19">19,20</a>]. In rare cases, ARN can present as acute angle-closure glaucoma [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1">Cytomegalovirus retinitis commonly observed in association with HIV infection may also manifest with retinal vasculitis. This disorder is characterized by a slowly progressive necrotizing retinitis of the posterior pole. (See  <a class="medical medical_review" href="/z/d/html/3746.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis"</a>.)</p><p></p><p class="headingAnchor" id="H1853375830"><span class="h2">Systemic immune-mediated causes</span><span class="headingEndMark"> — </span>Vasculitis of the retinal vessels may occur in association with a number of systemic diseases  (<a class="graphic graphic_table graphicRef56959" href="/z/d/graphic/56959.html" rel="external">table 1</a>). One classification system for the retinal vasculitides associated with systemic disease is by the type and size of the involved retinal vessels  (<a class="graphic graphic_table graphicRef55568" href="/z/d/graphic/55568.html" rel="external">table 2</a>) [<a href="#rid1">1</a>]. Knowledge of the systemic and ocular features in these disorders can help differentiate between the various causes.</p><p>Several systemic immune-mediated causes of retinal vasculitis are discussed below. The true prevalence of retinal vasculitis for each of these diseases is difficult to ascertain, and in some cases, is not known. One challenge is that retinal vasculitis can be difficult to differentiate from other causes (eg, thrombotic diseases of the retina can be indistinguishable from retinal vasculitis on angiography). Another issue is that many patients with systemic rheumatic diseases are not evaluated by ophthalmologists who would assess for retinal involvement. Finally, some ophthalmologists do not have expertise in retinal vasculitis or experience with the interpretation of <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> angiography. In many cases, wide-field fluorescein angiography is necessary to detect peripheral retinal vasculitis. In the authors' own experience, the use of wide-field angiography is critical for making the diagnosis of retinal vasculitis. Without angiographic imaging, in particular wide-field or peripheral angiography, cases of retinal vasculitis may be diagnosed as other retinal conditions since clinical findings without angiographic testing will result in alternative diagnoses.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behçet syndrome</strong> – Behçet syndrome is the systemic rheumatic disease most commonly associated with retinal vasculitis. The retinal veins are more commonly affected than the retinal arteries, manifesting clinically as recurrent retinal vaso-occlusive disease in association with the permanent loss of vision  (<a class="graphic graphic_picture graphicRef63242" href="/z/d/graphic/63242.html" rel="external">picture 4</a>). Upon examination, patients with acute attacks of retinal vasculitis often have retinal hemorrhages and edema in association with vitreous cells, findings that have to be differentiated from those resulting from viral retinitis. Retinal infiltrates, branch retinal vein occlusion, neovascularization, and vitritis are common posterior pole findings. (See  <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">"Clinical manifestations and diagnosis of Behçet syndrome", section on 'Ocular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic lupus erythematosus</strong> – Retinal vasculitis is an under-recognized manifestation of systemic lupus erythematosus (SLE). Mild and visually nonthreatening manifestations are common, consisting of cotton-wool spots with or without hemorrhages; they are observed in 3 to 30 percent of ambulatory and hospitalized patients with SLE, respectively [<a href="#rid21">21,22</a>]. The wide range of estimates is largely reflected by the limited quality of the data, with lower rates coming from retrospective studies and higher rates from prospective studies. In the experience of the authors, a fundus abnormality is frequently detected in patients with SLE who are actively flaring. In clinical practice, however, many patients with an active flare of SLE are not examined by a retina specialist, and visual symptoms are often not documented during the clinical evaluation.</p><p></p><p class="bulletIndent1">A case of retinal vasculitis has been reported as the presenting condition for the diagnosis of SLE [<a href="#rid23">23</a>]. Cotton-wool spots represent edematous and ischemic neuronal tissue. While many of these small retinal lesions may be appreciated on funduscopic examination, <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> angiography may be helpful in diagnosing subtle lesions, so the prevalence of angiographic retinopathy is likely even higher than that cited above [<a href="#rid24">24</a>]. Severe lupus retinopathy is characterized by severe ischemia because of vasculitic or thrombotic occlusion; it is observed more commonly in patients with active systemic disease and multiorgan involvement and, hence, correlates with decreased survival [<a href="#rid21">21,24-26</a>]. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Ophthalmologic involvement'</a>.)</p><p></p><p class="bulletIndent1">Retinal vasculitis in SLE typically affects the small arterioles and arteries and correlates with avascular areas on <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> angiography. More severe ischemia can result in neovascularization and hemorrhaging  (<a class="graphic graphic_diagnosticimage graphicRef50474" href="/z/d/graphic/50474.html" rel="external">image 2</a>). However, other nonspecific findings including capillary or venous dilatation, arteriolar constriction, and venous engorgement can also be seen in SLE. Very severe and sight-threatening retinal disease in SLE is typically associated with thrombotic occlusion of larger retinal vessels, findings that are often associated with antiphospholipid antibodies observed in antiphospholipid syndrome [<a href="#rid27">27</a>]. The larger retinal vessels affected in SLE can lead to branch or central retinal vein or artery occlusion, leading to profound and irreversible vision loss  (<a class="graphic graphic_picture graphicRef72037" href="/z/d/graphic/72037.html" rel="external">picture 5</a>) [<a href="#rid24">24,28,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Giant cell arteritis</strong> – Retinal vasculitis is a rare manifestation of ocular involvement related to giant cell arteritis (GCA, also known as Horton disease, cranial arteritis, and temporal arteritis) [<a href="#rid30">30</a>]. The more common ocular manifestation that can result in visual loss in GCA is arteritic anterior ischemic optic neuropathy, due to inflammatory occlusion of the posterior ciliary arteries; this accounts for 80 to 99 percent of visual loss attributable to GCA [<a href="#rid31">31</a>]. Retinal involvement due to GCA is manifested as peripapillary cotton-wool spots, which represent nerve fiber layer infarcts. Central retinal artery occlusion (CRAO) is the second most common cause of visual loss in GCA, affecting up to 20 percent of patients with ocular involvement [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis", section on 'Ocular involvement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polyarteritis nodosa</strong> – Ocular findings occur frequently in patients with polyarteritis nodosa [<a href="#rid32">32</a>]. However, retinal vasculitis is relatively rare among the ocular manifestations [<a href="#rid33">33</a>]. Anterior segment findings may include episcleritis, scleritis, corneal or scleral ulcers, and uncommonly iritis. Pseudotumor of the orbit or extraocular muscle dysfunction may also be observed. Although the choroidal arteries are most commonly affected, retinal vessel involvement may result in cotton-wool spots, retinal edema, vitritis, and hypertensive changes. Retinal venules may also be affected [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HLA-B27-associated conditions</strong> – The presence of the human leukocyte antigen B27 (HLA-B27) haplotype is strongly associated with the seronegative spondyloarthropathies, such as ankylosing spondylitis [<a href="#rid34">34,35</a>] (see  <a class="medical medical_review" href="/z/d/html/7792.html" rel="external">"Pathogenesis of spondyloarthritis"</a>). Although the main ocular complication in these conditions is recurrent anterior uveitis, posterior segment involvement including vitritis may be observed. The prevalence of posterior segment disease has varied from 4 to 17 percent in different studies [<a href="#rid36">36-38</a>]. Specific disorders included severe vitritis (93 percent), papillitis (84 percent), macular edema (38 percent), retinal vasculitis (24 percent), and vitreous and pars plana exudates (7 percent). The retinal vasculitis may affect both arteries and veins. Occasional patients develop central retinal vein occlusion with disc neovascularization or occult peripheral venular vasculitis [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsing polychondritis</strong> – Inflammation of the eye is a common finding in patients with relapsing polychondritis. In a retrospective study of 112 patients, for example, ocular manifestations were present in 21 percent at presentation and eventually developed in 57 percent [<a href="#rid39">39</a>]. The most common findings were scleritis and episcleritis (14 and 39 percent, respectively). In this same study, retinal findings were observed in 9 percent of patients; vasculitis of the retinal vessels was manifested as hemorrhages, vascular occlusions, and cotton-wool spots. These findings were not found at presentation but developed over time. (See  <a class="medical medical_review" href="/z/d/html/5606.html" rel="external">"Clinical manifestations of relapsing polychondritis", section on 'Eye involvement'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inflammatory bowel disease</strong> – Retinal vasculitis has been observed in patients with inflammatory bowel disease [<a href="#rid40">40</a>]. In one report of patients with Crohn disease, retinal vasculitis resulted in central retinal vein occlusion in one patient and in branch retinal artery occlusion in another [<a href="#rid41">41</a>]. In one of these patients, the retinal vasculitis preceded the diagnosis of Crohn disease. In the other, arteritis and phlebitis resulted in marked loss of vision [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/4064.html" rel="external">"Dermatologic and ocular manifestations of inflammatory bowel disease", section on 'Ocular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sarcoidosis</strong> – Ocular manifestations occur in 20 to 25 percent of patients with sarcoidosis [<a href="#rid43">43,44</a>]. The most common ocular manifestation is uveitis, which is frequently associated with retinal vasculitis [<a href="#rid44">44,45</a>]. (See  <a class="medical medical_review" href="/z/d/html/91259.html" rel="external">"Overview of extrapulmonary manifestations of sarcoidosis", section on 'Ocular'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multiple sclerosis</strong> – Optic neuritis is a common presenting manifestation of multiple sclerosis (MS), while retinal vasculitis is rare. The presence of retinal vasculitis in patients presenting with optic neuritis enhances the likelihood of the eventual development of MS. In one study of 50 patients with optic neuritis, for example, 25 percent had retinal abnormalities including retinal venous sheathing and <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> leakage without sheathing [<a href="#rid46">46</a>]. Retinal vasculitis was predictive for the development of MS in this cohort. Although most reports have found that retinal vasculitis in MS is limited to perivascular sheathing and vitreous cells, vascular occlusions, capillary closure, vitreous hemorrhage, and neovascularization can occur [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">"Evaluation and diagnosis of multiple sclerosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/96029.html" rel="external">"Clinical presentation, course, and prognosis of multiple sclerosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Granulomatosis with polyangiitis</strong> – The retinopathy associated with granulomatosis with polyangiitis (GPA) is characterized by involvement of the medium- to small-size arterioles; it occurs in less than 3 percent of cases, often resulting in cotton-wool spots and arteriolar occlusion, which are thought to occur due to external wall compression of tissue granulomas [<a href="#rid48">48-50</a>]. The retinopathy associated with GPA is <strong>not</strong> the classic retinal vasculitis picture. This occlusive retinal vasculitis is less common than optic neuropathy or optic disc vasculitis [<a href="#rid51">51</a>]. Because of the multifactorial pathophysiology of GPA, while mentioned here, it should not be placed in the same category as other diseases associated with typical retinal vasculitis [<a href="#rid49">49,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Susac syndrome</strong> – The angiopathy associated with Susac syndrome usually involves arterioles. The arterioles that are affected include cochlea, retinal, and brain. The severity of the arteriolar retinal vasculitis often results in branch retinal artery occlusions and is one of the hallmarks of the syndrome [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vogt-Koyanagi-Harada disease</strong> – Vogt-Koyanagi-Harada (VKH) disease usually presents with a classic uveitis and, if <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> angiograms are performed, retinal vasculitis is found in some patients with VKH disease. Other retinal patterns associated with VKH disease are more prevalent. It is unusual for VKH disease to present as a retinal vasculitis without the other more common retinal findings of VKH disease.</p><p></p><p class="headingAnchor" id="H1198275837"><span class="h2">Malignancies</span><span class="headingEndMark"> — </span>Retinal vasculitides have been seen in association with certain malignancies, as well as side effects of systemically administered immune checkpoint inhibitor and chemotherapy drugs. Some cancers documented to produce retinal vasculitis are lymphomas, multiple myelomas, leukemias, and melanomas.</p><p>Cancer drugs, especially checkpoint inhibitors such as <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a>, <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a>, and <a class="drug drug_general" data-topicid="119172" href="/z/d/drug information/119172.html" rel="external">cemiplimab</a> have also been associated with retinal vasculitis. In patients receiving atezolizumab, the retinal vasculitis can accompany acute macular neuroretinopathy (AMN), which affects central vision in addition to the diffuse retinal vasculitis [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H2699576490"><span class="h2">Primary ocular syndromes</span><span class="headingEndMark"> — </span>Although many forms of retinal vasculitis are associated with systemic inflammatory or infectious disease, a few forms of retinal vasculitis occur without extraocular or infectious involvement:</p><p class="bulletIndent1"><span class="glyph">●</span>Idiopathic retinal vasculitis</p><p class="bulletIndent1"><span class="glyph">●</span>Pars planitis syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Birdshot retinochoroidopathy</p><p class="bulletIndent1"><span class="glyph">●</span>Eales' disease</p><p class="bulletIndent1"><span class="glyph">●</span>Hemorrhagic occlusive retinal vasculitis</p><p class="bulletIndent1"><span class="glyph">●</span>Brolucizumab-associated occlusive retinal vasculitis</p><p></p><p>Retinal vasculitis associated with primary ocular disorders is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8231.html" rel="external">"Retinal vasculitis associated with primary ocular disorders"</a>.)</p><p class="headingAnchor" id="H265733481"><span class="h1">DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H3113924392"><span class="h2">When to suspect the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of retinal vasculitis may be suspected in a patient with an immune-mediated disorder or infectious disease that is known to be associated with retinal vasculitis (see <a class="local">'Etiology'</a> above) and who presents with any of the following ocular symptoms:</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased or blurry vision with or without pain</p><p class="bulletIndent1"><span class="glyph">●</span>Dry eye symptoms (tearing, burning sensation, redness, irritation)</p><p class="bulletIndent1"><span class="glyph">●</span>Lid inflammation or redness</p><p class="bulletIndent1"><span class="glyph">●</span>Eye mucous discharge</p><p class="bulletIndent1"><span class="glyph">●</span>Ocular or periocular pain</p><p class="bulletIndent1"><span class="glyph">●</span>Scalp and/or periocular tenderness</p><p></p><p>The initial diagnostic evaluation in a patient with suspected retinal vasculitis should focus on obtaining an expedited eye examination. Once the diagnosis is made, additional testing for the underlying disease is appropriate. (See <a class="local">'Evaluation for underlying disease'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h2">Clinical features</span></p><p class="headingAnchor" id="H1099306808"><span class="h3">Ocular symptoms</span><span class="headingEndMark"> — </span>The classic symptom of retinal vasculitis is a painless decrease in vision. Other symptoms may include a blind spot from ischemia-induced scotomas or floaters from vitritis. With macular involvement, patients may present with metamorphopsia (change in shape of an object) or abnormalities in color vision. Retinal vasculitis can also be asymptomatic.</p><p>It is uncertain whether patients develop retinal vasculitis during a flare of a systemic rheumatic disease or in isolation, largely because the underlying disease is often managed by non-ophthalmologists. There have been reported cases of retinal vasculitis as the first presenting sign of systemic lupus erythematosus (SLE), which may suggest that retinal vasculitis may occur in isolation from other signs of SLE [<a href="#rid23">23,54</a>]. Furthermore, an observational study of 69 patients with SLE found clinical evidence of retinopathy in 10 percent of patients [<a href="#rid55">55</a>]. Retinopathy was associated with SLE patients who had central nervous system involvement and the presence of anticardiolipin antibody, as well as a higher disease activity scores.</p><p class="headingAnchor" id="H3"><span class="h3">Ocular examination</span><span class="headingEndMark"> — </span>Abnormalities in the retinal vessels may be observed upon physical examination. Funduscopic findings include vascular sheathing (visible accumulation of inflammatory cells along vessel walls)  (<a class="graphic graphic_picture graphicRef54347" href="/z/d/graphic/54347.html" rel="external">picture 6</a>) and vitreous hemorrhage and cotton-wool spots. The peripheral vessels are often more involved than central arteries and veins, and there are frequently skip areas. With certain disorders such as sarcoidosis, lesions resembling candle-wax drippings or extensive perivascular inflammation may also be observed with indirect ophthalmoscopy.</p><p>The retinal vascular abnormalities are better demonstrated by <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> angiography  (<a class="graphic graphic_diagnosticimage graphicRef54057" href="/z/d/graphic/54057.html" rel="external">image 3</a>). One of the main changes on fluorescein angiography is perivascular staining, which reflects the increase in vascular permeability  (<a class="graphic graphic_picture graphicRef66049" href="/z/d/graphic/66049.html" rel="external">picture 7</a>). Cystoid macular edema, optic nerve edema, and capillary nonperfusion also may be seen.</p><p class="headingAnchor" id="H4"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of retinal vasculitis is purely clinical and can usually be made on funduscopic examination by an ophthalmologist experienced with uveitis. The gold standard for detecting retinal vasculitis is <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> angiography. Findings on fluorescein examination consistent with retinal vasculitis include vascular leakage (perivascular staining) and capillary nonperfusion [<a href="#rid56">56</a>]. It should be emphasized that mere vascular leakage is sufficient to diagnose retinal vasculitis but insufficient to diagnose a systemic vasculitis. This distinction is among the most important reasons why retinal vasculitis correlates poorly with systemic vasculitis.</p><p class="headingAnchor" id="H4158846599"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>While retinal vasculitis is a distinct clinical sign, it can often be confused with other retinal vascular pathologies as some of the symptoms or findings in retinal vasculitis may also occur in other conditions.</p><p>The differential diagnosis includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetic retinopathy (see  <a class="medical medical_review" href="/z/d/html/1783.html" rel="external">"Diabetic retinopathy: Classification and clinical features"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertensive retinopathy (see  <a class="medical medical_review" href="/z/d/html/3859.html" rel="external">"Ocular effects of hypertension"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sickle cell retinopathy (see  <a class="medical medical_review" href="/z/d/html/7119.html" rel="external">"Overview of the clinical manifestations of sickle cell disease", section on 'Retinopathy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radiation retinopathy (see  <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">"Delayed complications of cranial irradiation", section on 'Retinopathy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endophthalmitis (see  <a class="medical medical_review" href="/z/d/html/3418.html" rel="external">"Bacterial endophthalmitis"</a> and  <a class="medical medical_review" href="/z/d/html/16953.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retinal angiomatous proliferation (see  <a class="medical medical_review" href="/z/d/html/6901.html" rel="external">"Age-related macular degeneration"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary intraocular central nervous system (CNS) lymphoma has presented as retinal vasculitis [<a href="#rid57">57</a>] (see  <a class="medical medical_review" href="/z/d/html/4693.html" rel="external">"Primary central nervous system lymphoma: Clinical features, diagnosis, and extent of disease evaluation", section on 'Eyes'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retinal detachment (see  <a class="medical medical_review" href="/z/d/html/6910.html" rel="external">"Retinal detachment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infectious choroiditis (see  <a class="medical medical_review" href="/z/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multifocal or focal choroiditis (see  <a class="medical medical_review" href="/z/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="headingAnchor" id="H2480330856"><span class="h1">EVALUATION FOR UNDERLYING DISEASE</span><span class="headingEndMark"> — </span>Once a diagnosis of retinal vasculitis is made, the next step should be to determine if one of the systemic conditions described above is present (see <a class="local">'Etiology'</a> above). Establishing the correct diagnosis is essential if therapy and prognosis are to be optimized. In patients for whom the etiology remains uncertain based on the history and physical examination alone, selected laboratory testing may help elucidate the underlying etiology.</p><p>In almost all cases of retinal vasculitis that have systemic findings, these patients should be referred to a rheumatologist or other appropriate specialist if they are not already being followed by one. If retinal vasculitis is the only presenting manifestation, the eye physician should consider referring or co-managing with a rheumatologist if the eye clinician is not comfortable caring for patients with rheumatologic diseases.</p><p>The predominance or pattern of retinal vessel involvement can also help narrow the potential etiologies  (<a class="graphic graphic_table graphicRef55568" href="/z/d/graphic/55568.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H437102337"><span class="h2">History and examination</span><span class="headingEndMark"> — </span>Once retinal vasculitis is definitely diagnosed, the subsequent workup should include a thorough history, review of systems, and physical examination to help identify the underlying cause  (<a class="graphic graphic_table graphicRef56959" href="/z/d/graphic/56959.html" rel="external">table 1</a>).</p><p>The clinician should also question the patient regarding any history of a known systemic rheumatic disease, and whether they are experiencing other symptoms typically associated with their disease. However, in many cases, retinal vasculitis is the presenting condition for a systemic disease. In a retrospective study, 42.5 percent of patients with retinal vasculitis diagnosed in a single academic center, without known infectious or systemic disease, presented with their undiagnosed condition with retinal vasculitis [<a href="#rid58">58</a>].</p><p>Three clinical appearances of retinal vasculitis can present: diffuse, focal, and vaso-occlusive. While there is no histopathologic correlation to be made with these presentations, ophthalmoscopically, these different presentations can often be associated to a particular systemic etiology and can help a retina specialist determine potential systemic associations. For example, systemic conditions such as systemic lupus erythematosus (SLE) often present as diffuse retinal vasculitis. Infectious causes of retinal vasculitis such as toxoplasmosis usually present with focal patterns [<a href="#rid59">59</a>]. Vaso-oclusive disease has been seen with intravitreal injections of <a class="drug drug_general" data-topicid="122820" href="/z/d/drug information/122820.html" rel="external">brolucizumab</a> and novel anti-vascular endothelial growth factor (VEGF) injection [<a href="#rid60">60</a>].</p><p>Examples of some pertinent findings on history and physical examination are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with Behçet syndrome who have acute attacks of retinal vasculitis often have retinal hemorrhages and edema in association with vitreous cells, findings that have to be differentiated from those resulting from viral retinitis. Retinal infiltrates, branch retinal vein occlusion, neovascularization, and vitritis are common posterior pole findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Findings with <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> angiography in patients with sarcoidosis and ocular disease may include focal periphlebitis, diffuse capillary leakage, new vessel formation, and acute retinopathy [<a href="#rid61">61</a>]. The periphlebitis is described as resembling candle-wax drippings, a finding considered by some to be pathognomonic of sarcoidosis  (<a class="graphic graphic_picture graphicRef73985" href="/z/d/graphic/73985.html" rel="external">picture 8</a>) [<a href="#rid62">62</a>]. Focal periphlebitis primarily occurs around the vein and rarely occurs around arteries. Infiltration and vein occlusions of the retina are not usually observed in sarcoidosis but are seen in Behçet syndrome, a characteristic that can differentiate these two disorders [<a href="#rid61">61</a>]. Although vessel occlusions are not typical in sarcoidosis, involvement of the posterior segment is associated with a poor visual outcome [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent retinal vasculitis and posterior segment involvement must be entertained when evaluating a patient with seronegative spondyloarthropathy and human leukocyte antigen B27 (HLA-B27).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ophthalmic manifestations of cat scratch disease (CSD) are classically a neuroretinitis with a macular star.</p><p></p><p class="headingAnchor" id="H601696734"><span class="h2">Additional testing</span><span class="headingEndMark"> — </span>Only limited diagnostic testing is useful when an associated condition is not apparent despite a thorough medical history and physical examination. In patients in whom the history and examination does suggest a possible cause, diagnostic testing, which is focused upon confirming or excluding the suspected etiology, is warranted for confirmation of the specific diagnosis. In either situation, the use of multiple screening tests (a "shotgun approach") should be avoided.</p><p>The following routine tests and specialized serologic assays are appropriate to help identify or exclude systemic disease:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine tests:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count – Patients with systemic inflammatory conditions frequently have abnormalities of the white blood cell count, platelet count, or hematocrit.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum chemistry profile – This should include creatinine, blood urea nitrogen, electrolytes, albumin, total protein, and aminotransferases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urinalysis with microscopy – Urinalysis with microscopic examination of the urine sediment is essential to excluding glomerulonephritis, a common occurrence in some of the systemic diseases associated with scleritis, particularly granulomatosis with polyangiitis (GPA) and systemic lupus erythematosus (SLE).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute phase reactants – Patients with a systemic illness are more likely to have high acute phase reactants. Both the erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) could be checked. While these laboratory tests are of low yield diagnostically for most systemic rheumatic diseases, they are sometimes useful in following responses to therapy and in detecting disease flares.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specialized serologic assays:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antinuclear antibody testing – Antinuclear antibody (ANA) testing is useful for the exclusion of SLE and several other systemic autoimmune diseases. A strongly positive ANA assay should be followed by additional serologic testing to determine, if possible, the specific antigen responsible for the ANA positivity. This additional testing may include serum antibodies to double-stranded DNA, and antibodies to the Ro, La, Sm, or ribonucleoprotein (RNP) antigens. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Laboratory testing'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ANCA testing – Antineutrophil cytoplasmic antibodies (ANCA) assays are likely to be positive in patients with GPA, microscopic polyangiitis (MPA), or eosinophilic granulomatosis with polyangiitis (EGPA). (See  <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis", section on 'Testing for ANCA'</a>.)</p><p></p><p class="bulletIndent2">If an immunofluorescence assay is positive in either a cytoplasmic or perinuclear pattern (ie, C-ANCA or P-ANCA), then confirmation of the presence of the type of ANCA associated with systemic vasculitis, through enzyme immunoassays for antibodies to proteinase-3 or myeloperoxidase, is important.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Microbial serologies – In patients suspected of an infectious cause, serologic studies for syphilis and HIV should be performed. Other infectious serologic studies should be tailored to degree of suspicion for the specific infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging studies:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chest radiography (plain films) – Chest radiography should be performed in all patients to exclude infiltrates and nodules that might be associated with vasculitis, sarcoidosis, or infections such as tuberculosis (TB). Abnormal findings on chest radiographs should be defined further with computed tomography (CT) examination of the lungs and other imaging as required.</p><p></p><p>Additional testing depends upon the clinical assessment and upon the suspected underlying condition. It is also important to recognize that retinal vasculitis is an extremely uncommon manifestation of the classic systemic vasculitides, with the exception of Behçet syndrome [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults"</a>.)</p><p class="headingAnchor" id="H839274111"><span class="h1">MANAGEMENT AND PROGNOSIS</span><span class="headingEndMark"> — </span>The management of retinal vasculitis in the setting of a systemic rheumatic disease or infection is largely related to the treatment of the underlying disease. The management of retinal vasculitis associated with primary ocular syndromes is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8231.html" rel="external">"Retinal vasculitis associated with primary ocular disorders"</a>.)</p><p>In some cases, when patients present with retinal vasculitis, the associated underlying disease is unknown. If the patient is experiencing a decline in vision or if the vasculitis is encroaching on the macula, they have vision-threatening disease, and empiric therapy is initiated while the patient is also evaluated for associated conditions. For such patients, we recommend initial treatment with high doses of systemic glucocorticoids. We typically use an initial dose of the equivalent of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg (maximum 60 mg) daily.</p><p>The rationale for this approach is based on clinical experience and limited observational data, as well as extrapolation from the management of other vasculitides. A retrospective study of 29 patients with vision-threatening disease found that the administration of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (initial dose 1 mg/kg per day) was associated with visual improvement in 60 percent of patients [<a href="#rid64">64</a>]. In a retrospective cohort that included 236 patients with retinal vasculitis, the use of systemic glucocorticoids was associated with a reduced risk of vision loss (hazard ratio [HR] 0.36, 95% CI 0.15-0.82) [<a href="#rid65">65</a>]. When systemic glucocorticoids are used, they must gradually be tapered, typically over a period of months. The approach to the glucocorticoid dose reduction will vary, depending on whether the associated underlying disease is diagnosed. An example of glucocorticoid dosing that might be used is similar to the regimen for the treatment of giant cell arteritis. (See  <a class="medical medical_review" href="/z/d/html/8240.html" rel="external">"Treatment of giant cell arteritis", section on 'Glucocorticoids'</a> and  <a class="medical medical_review" href="/z/d/html/8240.html" rel="external">"Treatment of giant cell arteritis", section on 'Glucocorticoid tapering'</a>.)</p><p>In addition to systemic glucocorticoids, periocular or intraocular glucocorticoids such as <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide are also typically administered as adjunctive therapy when an infectious etiology for retinal vasculitis has been thoroughly ruled out.</p><p>If left untreated, retinal vasculitis may lead to progressive and extensive visual loss. There are limited data on the prognosis of patients with retinal vasculitis secondary to systemic disorders and infections. In retrospective cohort study, factors that were associated with an increased risk of vision loss included the presence of macular ischemia and edema [<a href="#rid65">65</a>]. In addition, retinal ischemia involving two or more quadrants of the retina was correlated with development of new blood vessel formation and ensuing complications. If neovascularization occurs, panretinal photocoagulation can be used to treat retinal neovascularization.</p><p class="headingAnchor" id="H2703966278"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110743.html" rel="external">"Society guideline links: Vasculitis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/118570.html" rel="external">"Society guideline links: Uveitis"</a>.)</p><p class="headingAnchor" id="H366931"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Causes</strong> – Retinal vasculitis is characterized by inflammation of the vessels of the retina. Retinal vasculitis can occur in association with an underlying infectious or systemic disease, as part of an ocular disease, or it can be idiopathic  (<a class="graphic graphic_table graphicRef56959" href="/z/d/graphic/56959.html" rel="external">table 1</a>). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1">The most common cause of infectious retinal vasculitis is toxoplasmosis, followed by tuberculosis (TB), syphilis, and herpes viral infections. Other infectious causes include Whipple's disease, syphilis, Lyme disease, and cat scratch disease (CSD). (See <a class="local">'Infectious causes'</a> above.)</p><p></p><p class="bulletIndent1">Systemic disorders associated with retinal vasculitis include Behçet syndrome, systemic lupus erythematosus (SLE), various forms of systemic vasculitis, and others  (<a class="graphic graphic_table graphicRef56959" href="/z/d/graphic/56959.html" rel="external">table 1</a>). One classification system for the retinal vasculitides associated with systemic disease is by the type and size of the involved retinal vessels  (<a class="graphic graphic_table graphicRef55568" href="/z/d/graphic/55568.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">A variety of uveitis syndromes occur without extraocular or infectious involvement including idiopathic retinal vasculitis, pars planitis syndrome, birdshot retinochoroidopathy, Eales' disease, and hemorrhagic occlusive retinal vasculitis. (See <a class="local">'Primary ocular syndromes'</a> above and  <a class="medical medical_review" href="/z/d/html/8231.html" rel="external">"Retinal vasculitis associated with primary ocular disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The classic symptom of retinal vasculitis is a painless decrease in vision. Other symptoms may include a blind spot from ischemia-induced scotomas or floaters from vitritis. With macular involvement, patients may present with metamorphopsia (change in shape of an object) or abnormalities in color vision. Retinal vasculitis can also be asymptomatic. (See <a class="local">'Ocular symptoms'</a> above.)</p><p></p><p class="bulletIndent1">The diagnosis of retinal vasculitis may be suspected in a patient with an immune-mediated disorder or infectious disease that is known to be associated with retinal vasculitis and who presents with any of the following ocular symptoms (see <a class="local">'When to suspect the diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreased or blurry vision</p><p class="bulletIndent2"><span class="glyph">•</span>Dry eye symptoms (tearing, burning sensation, redness, irritation)</p><p class="bulletIndent2"><span class="glyph">•</span>Lid inflammation or redness</p><p class="bulletIndent2"><span class="glyph">•</span>Eye mucous discharge</p><p class="bulletIndent2"><span class="glyph">•</span>Ocular or periocular pain</p><p class="bulletIndent2"><span class="glyph">•</span>Scalp and/or periocular tenderness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation and diagnosis</strong> – The initial diagnostic evaluation in a patient with suspected retinal vasculitis should focus on obtaining an expedited eye examination. The diagnosis of retinal vasculitis is clinical and can usually be made on funduscopic examination by an ophthalmologist experienced with uveitis.</p><p></p><p class="bulletIndent1">The gold standard for detecting retinal vasculitis is <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> angiography. Findings on fluorescein examination consistent with retinal vasculitis include vascular leakage (perivascular staining) and capillary nonperfusion. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Ocular examination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent evaluation</strong> – Once a diagnosis of retinal vasculitis is made, the subsequent workup should include a thorough history, review of systems, and physical examination to help identify the underlying cause  (<a class="graphic graphic_table graphicRef56959" href="/z/d/graphic/56959.html" rel="external">table 1</a>). Only limited diagnostic testing is useful when an associated condition is not apparent despite a thorough medical history and physical examination. (See <a class="local">'Evaluation for underlying disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The management of retinal vasculitis in the setting of a systemic rheumatic disease or infection is largely related to the treatment of the underlying disease.</p><p></p><p class="bulletIndent1">Some patients present with retinal vasculitis without a known associated underlying disease. If such a patient is experiencing a decline in vision or if the vasculitis is encroaching on the macula, empiric therapy is initiated while the patient is evaluated for associated conditions. Left untreated, retinal vasculitis may lead to progressive and extensive visual loss. Thus, for such patients, we recommend initial treatment with high doses of systemic glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). We typically use an initial dose of the equivalent of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg (maximum 60 mg) daily. (See <a class="local">'Management and prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H994998832"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael Tolentino, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Stanford MR, Graham EM. Systemic associations of retinal vasculitis. Int Ophthalmol Clin 1991; 31:23.</a></li><li><a class="nounderline abstract_t">Henderly DE, Genstler AJ, Smith RE, Rao NA. Changing patterns of uveitis. Am J Ophthalmol 1987; 103:131.</a></li><li><a class="nounderline abstract_t">Dutt AK, Moers D, Stead WW. Short-course chemotherapy for extrapulmonary tuberculosis. Nine years' experience. Ann Intern Med 1986; 104:7.</a></li><li><a class="nounderline abstract_t">Donahue HC. Ophthalmologic experience in a tuberculosis sanatorium. Am J Ophthalmol 1967; 64:742.</a></li><li><a class="nounderline abstract_t">Cangemi FE, Friedman AH, Josephberg R. Tuberculoma of the choroid. Ophthalmology 1980; 87:252.</a></li><li><a class="nounderline abstract_t">ILLINGWORTH RS, WRIGHT T. Tubercles of the choroid. Br Med J 1948; 2:365.</a></li><li><a class="nounderline abstract_t">Rosen PH, Spalton DJ, Graham EM. Intraocular tuberculosis. Eye (Lond) 1990; 4 ( Pt 3):486.</a></li><li><a class="nounderline abstract_t">Fountain JA, Werner RB. Tuberculous retinal vasculitis. Retina 1984; 4:48.</a></li><li><a class="nounderline abstract_t">Psilas K, Aspiotis M, Petroutsos G, et al. Antituberculosis therapy in the treatment of peripheral uveitis. Ann Ophthalmol 1991; 23:254.</a></li><li><a class="nounderline abstract_t">Avila MP, Jalkh AE, Feldman E, et al. Manifestations of Whipple's disease in the posterior segment of the eye. Arch Ophthalmol 1984; 102:384.</a></li><li><a class="nounderline abstract_t">Lo Monaco A, Govoni M, Zelante A, et al. Whipple disease: unusual presentation of a protean and sometimes confusing disease. Semin Arthritis Rheum 2009; 38:403.</a></li><li class="breakAll">Whitcup S, Raizman M. Spirochetal infections and the eye. In: Principles and Practice of Ophthalmology, Alberts D, Jakobiec F (Eds), WB Saunders, 1994. p.3078.</li><li><a class="nounderline abstract_t">Raja H, Starr MR, Bakri SJ. Ocular manifestations of tick-borne diseases. Surv Ophthalmol 2016; 61:726.</a></li><li><a class="nounderline abstract_t">Grinager HS, Krason DA, Olsen TW. Lyme disease: resolution of a serous retinal detachment and chorioretinal folds after antibiotic therapy. Retin Cases Brief Rep 2012; 6:232.</a></li><li><a class="nounderline abstract_t">Tolou C, Mahieu L, Martin-Blondel G, et al. Posterior segment involvement in cat-scratch disease: A case series. J Fr Ophtalmol 2015; 38:974.</a></li><li><a class="nounderline abstract_t">Mabra D, Yeh S, Shantha JG. Ocular manifestations of bartonellosis. Curr Opin Ophthalmol 2018; 29:582.</a></li><li><a class="nounderline abstract_t">Ludwig IH, Zegarra H, Zakov ZN. The acute retinal necrosis syndrome. Possible herpes simplex retinitis. Ophthalmology 1984; 91:1659.</a></li><li><a class="nounderline abstract_t">Kaushik S, Lomi N, Singh MP, et al. Acute retinal necrosis presenting as bilateral acute angle closure. Lancet 2014; 384:636.</a></li><li><a class="nounderline abstract_t">Fisher JP, Lewis ML, Blumenkranz M, et al. The acute retinal necrosis syndrome. Part 1: Clinical manifestations. Ophthalmology 1982; 89:1309.</a></li><li><a class="nounderline abstract_t">Culbertson WW, Blumenkranz MS, Pepose JS, et al. Varicella zoster virus is a cause of the acute retinal necrosis syndrome. Ophthalmology 1986; 93:559.</a></li><li><a class="nounderline abstract_t">Gold DH, Morris DA, Henkind P. Ocular findings in systemic lupus erythematosus. Br J Ophthalmol 1972; 56:800.</a></li><li><a class="nounderline abstract_t">Dunn JP, Noorily SW, Petri M, et al. Antiphospholipid antibodies and retinal vascular disease. Lupus 1996; 5:313.</a></li><li><a class="nounderline abstract_t">Storey P, Ter-Zakarian A, Rao N, Rodger D. SEVERE BILATERAL RETINAL VASCULAR OCCLUSION AS FIRST PRESENTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME. Retin Cases Brief Rep 2017; 11 Suppl 1:S44.</a></li><li><a class="nounderline abstract_t">Lanham JG, Barrie T, Kohner EM, Hughes GR. SLE retinopathy: evaluation by fluorescein angiography. Ann Rheum Dis 1982; 41:473.</a></li><li><a class="nounderline abstract_t">Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum 1988; 31:1105.</a></li><li><a class="nounderline abstract_t">Hall S, Buettner H, Luthra HS. Occlusive retinal vascular disease in systemic lupus erythematosus. J Rheumatol 1984; 11:846.</a></li><li><a class="nounderline abstract_t">Giorgi D, Pace F, Giorgi A, et al. Retinopathy in systemic lupus erythematosus: pathogenesis and approach to therapy. Hum Immunol 1999; 60:688.</a></li><li><a class="nounderline abstract_t">Coppeto J, Lessell S. Retinopathy in systemic lupus erythematosus. Arch Ophthalmol 1977; 95:794.</a></li><li><a class="nounderline abstract_t">Jabs DA, Fine SL, Hochberg MC, et al. Severe retinal vaso-occlusive disease in systemic lupus erythematous. Arch Ophthalmol 1986; 104:558.</a></li><li><a class="nounderline abstract_t">Papakostas TD, Jakobiec FA, Stagner AM, et al. Small-Caliber Retinal Vasculitis Associated With Giant Cell Arteritis: A New Finding. Ophthalmic Surg Lasers Imaging Retina 2016; 47:1054.</a></li><li><a class="nounderline abstract_t">De Smit E, O'Sullivan E, Mackey DA, Hewitt AW. Giant cell arteritis: ophthalmic manifestations of a systemic disease. Graefes Arch Clin Exp Ophthalmol 2016; 254:2291.</a></li><li><a class="nounderline abstract_t">Morgan CM, Foster CS, D'Amico DJ, Gragoudas ES. Retinal vasculitis in polyarteritis nodosa. Retina 1986; 6:205.</a></li><li><a class="nounderline abstract_t">Akova YA, Jabbur NS, Foster CS. Ocular presentation of polyarteritis nodosa. Clinical course and management with steroid and cytotoxic therapy. Ophthalmology 1993; 100:1775.</a></li><li><a class="nounderline abstract_t">Ebringer A, Baines M, Ptaszynska T. Spondyloarthritis, uveitis, HLA-B27 and Klebsiella. Immunol Rev 1985; 86:101.</a></li><li><a class="nounderline abstract_t">Lee DA, Barker SM, Su WP, et al. The clinical diagnosis of Reiter's syndrome. Ophthalmic and nonophthalmic aspects. Ophthalmology 1986; 93:350.</a></li><li><a class="nounderline abstract_t">Rodriguez A, Akova YA, Pedroza-Seres M, Foster CS. Posterior segment ocular manifestations in patients with HLA-B27-associated uveitis. Ophthalmology 1994; 101:1267.</a></li><li><a class="nounderline abstract_t">Rothova A, Buitenhuis HJ, Meenken C, et al. Uveitis and systemic disease. Br J Ophthalmol 1992; 76:137.</a></li><li><a class="nounderline abstract_t">Mapstone R, Woodrow JC. HL-A 27 and acute anterior uveitis. Br J Ophthalmol 1975; 59:270.</a></li><li><a class="nounderline abstract_t">Isaak BL, Liesegang TJ, Michet CJ Jr. Ocular and systemic findings in relapsing polychondritis. Ophthalmology 1986; 93:681.</a></li><li><a class="nounderline abstract_t">Matsuo T, Yamaoka A. Retinal vasculitis revealed by fluorescein angiography in patients with inflammatory bowel disease. Jpn J Ophthalmol 1998; 42:398.</a></li><li><a class="nounderline abstract_t">Ruby AJ, Jampol LM. Crohn's disease and retinal vascular disease. Am J Ophthalmol 1990; 110:349.</a></li><li><a class="nounderline abstract_t">Duker JS, Brown GC, Brooks L. Retinal vasculitis in Crohn's disease. Am J Ophthalmol 1987; 103:664.</a></li><li><a class="nounderline abstract_t">Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med 1974; 57:847.</a></li><li><a class="nounderline abstract_t">Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol 1986; 102:297.</a></li><li><a class="nounderline abstract_t">Patterson M, Bergstrom CS, Clark WL, et al. SEVERE PANUVEITIS, RETINAL VASCULITIS, AND OPTIC DISK GRANULOMA SECONDARY TO SARCOIDOSIS. Retin Cases Brief Rep 2016; 10:341.</a></li><li><a class="nounderline abstract_t">Lightman S, McDonald WI, Bird AC, et al. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987; 110 ( Pt 2):405.</a></li><li><a class="nounderline abstract_t">Graham EM, Francis DA, Sanders MD, Rudge P. Ocular inflammatory changes in established multiple sclerosis. J Neurol Neurosurg Psychiatry 1989; 52:1360.</a></li><li><a class="nounderline abstract_t">Spalton DJ, Graham EM, Page NG, Sanders MD. Ocular changes in limited forms of Wegener's granulomatosis. Br J Ophthalmol 1981; 65:553.</a></li><li><a class="nounderline abstract_t">Wang M, Khurana RN, Sadda SR. Central retinal vein occlusion in Wegener's granulomatosis without retinal vasculitis. Br J Ophthalmol 2006; 90:1435.</a></li><li><a class="nounderline abstract_t">Morell-Dubois S, Quéméneur T, Bourdon F, et al. [Central retinal artery occlusion in Wegener'granulomatosis]. Rev Med Interne 2007; 28:33.</a></li><li class="breakAll">Jabs D. Rheumatic disease. In: Retina, Ryan S (Ed), Mosby, St Louis 1994.</li><li><a class="nounderline abstract_t">Yepez JB, Murati FA, Pettito M, Arevalo JF. INTRAVITREAL TRIAMCINOLONE IN SUSAC SYNDROME. Retin Cases Brief Rep 2017; 11:236.</a></li><li><a class="nounderline abstract_t">Emens LA, Davis SL, Oliver SCN, et al. Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis. JAMA Ophthalmol 2019; 137:96.</a></li><li><a class="nounderline abstract_t">Monov S, Hristova R, Dacheva R, et al. Acute necrotizing retinal vasculitis as onset of systemic lupus erythematosus: A case report. Medicine (Baltimore) 2017; 96:e5754.</a></li><li><a class="nounderline abstract_t">Ushiyama O, Ushiyama K, Koarada S, et al. Retinal disease in patients with systemic lupus erythematosus. Ann Rheum Dis 2000; 59:705.</a></li><li><a class="nounderline abstract_t">Agarwal A, Afridi R, Agrawal R, et al. Multimodal Imaging in Retinal Vasculitis. Ocul Immunol Inflamm 2017; 25:424.</a></li><li><a class="nounderline abstract_t">Katoch D, Bansal R, Nijhawan R, Gupta A. Primary intraocular central nervous system lymphoma masquerading as diffuse retinal vasculitis. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">Shulman S, Kramer M, Amer R, et al. CHARACTERISTICS AND LONG-TERM OUTCOME OF PATIENTS WITH NONINFECTIOUS RETINAL VASCULITIS. Retina 2015; 35:2633.</a></li><li><a class="nounderline abstract_t">Rosenbaum JT, Robertson JE Jr, Watzke RC. Retinal vasculitis--a primer. West J Med 1991; 154:182.</a></li><li><a class="nounderline abstract_t">Witkin AJ, Hahn P, Murray TG, et al. Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab. J Vitreoretin Dis 2020; 4:269.</a></li><li><a class="nounderline abstract_t">Sanders MD, Graham EM. Retinal vasculitis. Postgrad Med J 1988; 64:488.</a></li><li><a class="nounderline abstract_t">Sanders MD, Shilling JS. Retinal, choroidal, and optic disc involvement in sarcoidosis. Trans Ophthalmol Soc U K 1976; 96:140.</a></li><li><a class="nounderline abstract_t">Rosenbaum JT, Ku J, Ali A, et al. Patients with retinal vasculitis rarely suffer from systemic vasculitis. Semin Arthritis Rheum 2012; 41:859.</a></li><li><a class="nounderline abstract_t">Howe LJ, Stanford MR, Edelsten C, Graham EM. The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis. Eye (Lond) 1994; 8 ( Pt 4):443.</a></li><li><a class="nounderline abstract_t">Sharief L, Lightman S, Blum-Hareuveni T, et al. Clinical Outcome of Retinal Vasculitis and Predictors for Prognosis of Ischemic Retinal Vasculitis. Am J Ophthalmol 2017; 177:206.</a></li></ol></div><div id="topicVersionRevision">Topic 8232 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1715333" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Systemic associations of retinal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3812615" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Changing patterns of uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3940507" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Short-course chemotherapy for extrapulmonary tuberculosis. Nine years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6061532" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ophthalmologic experience in a tuberculosis sanatorium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7422265" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Tuberculoma of the choroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18877342" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tubercles of the choroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2209914" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Intraocular tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6729264" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tuberculous retinal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929092" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antituberculosis therapy in the treatment of peripheral uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6200096" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Manifestations of Whipple's disease in the posterior segment of the eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18538828" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Whipple disease: unusual presentation of a protean and sometimes confusing disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18538828" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Whipple disease: unusual presentation of a protean and sometimes confusing disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27060746" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ocular manifestations of tick-borne diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25389719" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lyme disease: resolution of a serous retinal detachment and chorioretinal folds after antibiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26545331" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Posterior segment involvement in cat-scratch disease: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30124532" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ocular manifestations of bartonellosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6097854" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The acute retinal necrosis syndrome. Possible herpes simplex retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25131983" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acute retinal necrosis presenting as bilateral acute angle closure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7162777" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The acute retinal necrosis syndrome. Part 1: Clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3014414" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Varicella zoster virus is a cause of the acute retinal necrosis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4647128" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ocular findings in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8869905" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antiphospholipid antibodies and retinal vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27548039" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : SEVERE BILATERAL RETINAL VASCULAR OCCLUSION AS FIRST PRESENTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7125716" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : SLE retinopathy: evaluation by fluorescein angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3422014" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lupus retinopathy. Patterns, associations, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6084063" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Occlusive retinal vascular disease in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10439314" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Retinopathy in systemic lupus erythematosus: pathogenesis and approach to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/871263" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Retinopathy in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3954661" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Severe retinal vaso-occlusive disease in systemic lupus erythematous.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27842201" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Small-Caliber Retinal Vasculitis Associated With Giant Cell Arteritis: A New Finding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27495301" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Giant cell arteritis: ophthalmic manifestations of a systemic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2883710" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Retinal vasculitis in polyarteritis nodosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7903120" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ocular presentation of polyarteritis nodosa. Clinical course and management with steroid and cytotoxic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2412951" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Spondyloarthritis, uveitis, HLA-B27 and Klebsiella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3486396" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The clinical diagnosis of Reiter's syndrome. Ophthalmic and nonophthalmic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8035991" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Posterior segment ocular manifestations in patients with HLA-B27-associated uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1540555" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Uveitis and systemic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1138855" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : HL-A 27 and acute anterior uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3523358" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ocular and systemic findings in relapsing polychondritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9822971" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Retinal vasculitis revealed by fluorescein angiography in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2220968" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Crohn's disease and retinal vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3555098" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Retinal vasculitis in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4432869" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Course and prognosis of sarcoidosis around the world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3752193" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Ocular involvement in chronic sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26650564" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : SEVERE PANUVEITIS, RETINAL VASCULITIS, AND OPTIC DISK GRANULOMA SECONDARY TO SARCOIDOSIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3567529" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2614430" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ocular inflammatory changes in established multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7295616" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ocular changes in limited forms of Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17057178" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Central retinal vein occlusion in Wegener's granulomatosis without retinal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166634" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : [Central retinal artery occlusion in Wegener'granulomatosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166634" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : [Central retinal artery occlusion in Wegener'granulomatosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27276498" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : INTRAVITREAL TRIAMCINOLONE IN SUSAC SYNDROME.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383154" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28079801" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Acute necrotizing retinal vasculitis as onset of systemic lupus erythematosus: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10976084" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Retinal disease in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28696172" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Multimodal Imaging in Retinal Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23632616" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Primary intraocular central nervous system lymphoma masquerading as diffuse retinal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26035402" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : CHARACTERISTICS AND LONG-TERM OUTCOME OF PATIENTS WITH NONINFECTIOUS RETINAL VASCULITIS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2006565" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Retinal vasculitis--a primer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32789284" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3074280" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Retinal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1070843" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Retinal, choroidal, and optic disc involvement in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22177107" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Patients with retinal vasculitis rarely suffer from systemic vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7821470" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The efficacy of systemic corticosteroids in sight-threatening retinal vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263735" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical Outcome of Retinal Vasculitis and Predictors for Prognosis of Ischemic Retinal Vasculitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
